Nuveen Asset Management LLC Has $2.55 Million Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Nuveen Asset Management LLC boosted its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 73.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 586,616 shares of the company's stock after purchasing an additional 248,850 shares during the period. Nuveen Asset Management LLC owned 1.15% of Cardiff Oncology worth $2,546,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new stake in Cardiff Oncology in the 4th quarter valued at $25,000. Raymond James Financial Inc. acquired a new stake in shares of Cardiff Oncology during the fourth quarter worth $56,000. Voya Investment Management LLC bought a new stake in shares of Cardiff Oncology in the fourth quarter valued at about $57,000. Caxton Corp acquired a new position in shares of Cardiff Oncology in the fourth quarter valued at about $58,000. Finally, Mariner LLC acquired a new stake in Cardiff Oncology during the fourth quarter worth approximately $61,000. Institutional investors and hedge funds own 16.29% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright raised their target price on Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a report on Friday, May 9th.

Cardiff Oncology Price Performance

Shares of Cardiff Oncology stock traded up $0.26 during trading on Friday, hitting $3.88. The company's stock had a trading volume of 1,152,099 shares, compared to its average volume of 1,155,039. The stock has a market cap of $258.12 million, a price-to-earnings ratio of -4.13 and a beta of 1.61. Cardiff Oncology, Inc. has a 52 week low of $2.01 and a 52 week high of $5.64. The stock has a 50-day moving average price of $2.90 and a two-hundred day moving average price of $3.46.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.09 million. On average, equities analysts predict that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.